Overview

Cardiotoxicity in breast cancer has emerged as a significant concern due to the increasing use of multimodal therapies, which combine different treatment modalities such as chemotherapy, targeted therapies, and radiation. While these therapies have improved survival rates, they can also have detrimental effects on the heart, leading to cardiotoxicity.

For the second edition of this series of weekly educational broadcasts, brought to you by IC-OS's partnership with Radcliffe, Dr Paul Cottu (Institut Curie, FR), Dr Mariana Mirabel (Institut Mutualiste Montsouris, FR) and Dr Francesco Cribari (Institut Mutualiste Montsouris, FR) discuss the challenges that multimodal therapies present for heart damage when used to treat breast cancer. 

The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits. 

This broadcast is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.

The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS are collectively improving the overall outcomes including survival and quality of life. IC-OS aim to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.

Support Statement

This is an independent activity run by the International Cardio-Oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. The IC-OS has been provided support to deliver this webinar series by AstraZeneca, BMS/Pfizer Alliance and Roche through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.